Navigation Links
Allos Therapeutics to Present at the Bear Stearns 20th Annual Healthcare Conference
Date:9/4/2007

WESTMINSTER, Colo., Sept. 4 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. (Nasdaq: ALTH), a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer, today announced that Paul L. Berns, President and CEO, will present a corporate overview at the Bear Stearns 20th Annual Healthcare Conference in New York.

The Company's presentation will take place at 9:00 a.m. (Eastern) on Monday, September 10, 2007. There will be a live webcast of the presentation, which will be accessible through a link posted on the Allos website home page and investor relations section. The webcast will be available for replay on Allos' website through September 21, 2007.

About Allos Therapeutics, Inc.

Allos Therapeutics is a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer. The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 trial in patients with relapsed or refractory peripheral T-cell lymphoma. The Company is also investigating PDX in patients with non-small cell lung cancer and a range of other lymphoma sub-types. The Company's other product candidate is RH1, a targeted chemotherapeutic agent, for which the company expects to initiate a Phase 1 trial in patients with advanced solid tumors in the second half of 2007. For additional information, please visit the Company's website at http://www.allos.com.

Safe Harbor Statement

The anticipated presentation will contain forward-looking statements that involve significant risks and uncertainties. Additional information concerning these forward-looking statements and other factors that may cause actual results to differ materially from those anticipated in the forward- looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2006 and in the Company's other periodic reports and filings with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in the presentation. All forward-looking statements are based on information currently available to the Company on the date thereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this presentation, except as required by law.


'/>"/>
SOURCE Allos Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
3. Wisconsin firms to present at Cleantech venture capital event
4. New Sonic Foundry search engine finds words, phrases in video presentations
5. Lone Wisconsin firm to present at InvestMidwest
6. Sonic Foundry creates search engine for 7,000 expert video presentations
7. InvestMidWest calls for business presentations
8. Wicab to present BrainPort at Boston conference
9. Three more Wisconsin firms to present at venture forum
10. Six Wisconsin firms to present at BIO Mid-America VentureForum
11. New Health and Human Services representative for Midwest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... February 09, 2016 , ... ... President for Public Policy for the National Organization for Rare Disorders (NORD). Dorman ... to ensure their voices are heard throughout the drug regulatory review process. , ...
(Date:2/9/2016)... YORK , Feb. 9, 2016 This ... analyzes the current and future prospects of the market ... this report include companies engaged in the manufacture of ... an executive summary with a market snapshot providing the ... scope of this report. This section also provides the ...
(Date:2/9/2016)... Three-Year Initiative Supports Next Generation of Medical Geneticists ... Camp Experiences SHPG ... lives of children born with rare diseases, as well as the ... announcing a new initiative designed to positively affect the lives of ... rare disease care. --> To mark the company,s founding ...
(Date:2/9/2016)... 2016 DelveInsight,s, "Protein-Tyrosine ... provides in depth insights on the pipeline ... Protein-Tyrosine Phosphatase 1B (PTP1B) Inhibitors. The DelveInsight,s ... stages of development including Discovery, Pre-clinical, IND, ... Preregistration. Report covers the product clinical trials ...
Breaking Biology Technology:
(Date:1/21/2016)... 2016 --> ... research report "Emotion Detection and Recognition Market by Technology (Bio-Sensors, ... Expression, Voice Recognition and Others), Services, Application Areas, ... 2020", published by MarketsandMarkets, the global Emotion Detection ... 22.65 Billion by 2020, at a CAGR of ...
(Date:1/15/2016)... 2016 Recent publicized breaches in cyber security ... ways to ensure data security and user authentication in ... Android that ties a user,s mobile number ... a hardware authorization token. Customer service agents who employ ... their KodeKey enabled device to verify their identity.  Companies ...
(Date:1/8/2016)... MANCHESTER, United Kingdom , Jan. 8, 2016   ... diagnostic products, today announced the closing of a $9 million ... Proceeds from the financing will be used to accelerate the ... for detecting early-stage pressure ulcers. United ... receiving CE Mark approval. The device,s introduction has been met ...
Breaking Biology News(10 mins):